Category Archives: Epigenetics

CMI published a business research report on Epigenetics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 20202027. Epigenetics Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The information is gathered based on modern floats and requests identified with the administrations and items.

Click To Get Free PDF Brochure: https://www.coherentmarketinsights.com/insight/request-pdf/1772

The worldwide Epigenetics Market report stresses the most recent advancements, development, new chances, and lethargic traps. It gives a comprehensive position of the worldwide Epigenetics Market. The Epigenetics Market research report covers the present scenario and the growth prospects of the global Epigenetics Market industry for 2020-2027. The report enlists several important factors, starting from the basics to advanced market intelligence which play a crucial part in strategizing. Epigenetics Market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Epigenetics Market industry.

Leading Market Player Profile Included in This Report is: Illumina Inc., Thermo Fisher Scientific Inc., Merck Millipore Limited, Bio-Rad Laboratories, Inc., Qiagen Inc., Zymo Research Corporation, Diagenode s. a., Enzo Life Sciences, Inc. and New England Biolabs Inc.

Most of the information assembled is exhibited in a graphical frame alongside the related measurements. The Epigenetics Market report exhibits the working of the fundamental market players, providers, and merchants in detail. The report likewise features the limitations and drivers affecting the Epigenetics Market.

The report likewise incorporates a fundamental profile and data of all the significant market players at present dynamic in the worldwide Epigenetics Market. The organizations canvassed in the report can be assessed based on their most recent advancements, monetary and business diagram, item portfolio, enter drifts in the market, long haul and here and now business methodologies by the organizations with the end goal to remain aggressive in the market.

Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/1772

Important Features of the Epigenetics Market:

To build up a far-reaching, verifiable, every year refreshed and financially savvy data dependent on execution, capacities, objectives, and systems of the worlds driving organizations.

To help current providers reasonably evaluate their money related, advertising and innovative capacities opposite driving contenders.

To help potential market contestants in assessing imminent acquisitions and joint endeavor hopefuls.

To supplement associations inner rival data gathering endeavors by giving vital investigation, information understanding, and knowledge.

To distinguish the slightest focused market specialties with huge development potential.

Global Epigenetics Market: Regional Segment Analysis

North America (U.S., Canada, Mexico),

Europe (Germany, U.K., France, Italy, Russia, Spain etc),

South America (Brazil, Argentina etc)

Middle East & Africa (Saudi Arabia, South Africa etc).

Asia-Pacific (China, Japan, India)

In order to get a deeper view of Market Size, competitive landscape is provided i.e. Revenue (Million USD) by Players (2015-2020), Revenue Market Share (%) by Players (2015-2020) and further a qualitative analysis is made towards market concentration rate, product/service differences, new entrants and the technological trends in future.

An Overview of the Impact of COVID-19 on this Market:

The pandemic of COVID-19 continues to expand and impact over 175 countries and territories. Although the outbreak appears to have slowed in China, COVID-19 has impacted globally. The pandemic could affect three main aspects of the global economy: production, supply chain, and firms and financial markets. National governments have announced largely uncoordinated, country-specific responses to the virus. As authorities encourage social distancing and consumers stay indoors, several businesses are hit. However, coherent, coordinated, and credible policy responses are expected to offer the best chance at limiting the economic fallout.

National governments and international bodies are focused on adopting collaborative efforts to encourage financial institutions to meet the financial needs of customers and members affected by the coronavirus. However, there are some sectors that have remained unscathed from the impact of the pandemic and there are some that are hit the hardest.

We, at Coherent Market Insights, understand the economic impact on various sectors and markets. Using our holistic market research methodology, we are focused on aiding your business sustain and grow during COVID-19 pandemics. With deep expertise across various industries-no matter how large or small- and with a team of highly experienced and dedicated analysts, Coherent Market Insights will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

We Offer Customized Report, Click @ https://www.coherentmarketinsights.com/insight/request-customization/1772

Available Customizations

As per specific needs customizations of the given market data is also available. Talk to our research consultant to design an exclusive report as per your research needs like Regional and country-level analysis of market by end-use, detailed analysis and profiles of additional market players.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Phone: US +12067016702 / UK +4402081334027Email: [emailprotected]

Read more here:
Epigenetics Market 2020-2026: Global economy,Financial Share, Prominent Players,Competitive Environment,Types and Applications of Product/Service...

Ever had a bad experience with a prescription?

Ever thought it was an allergic reaction to a medication?

In 2017 I had a significant abdominal surgery that required me to take pain medication, anti-inflammatories, and antibiotics. The surgery was supposed to help with a significant abdominal umbilical hernia. It occurred on a Wednesday, and by Monday, I was having a significant reaction to the pain medication, where my FACE went NUMB. Talk about scary.

Leading up to the surgery, I had taken part in 2 appointments where I discussed previous bad reactions to the pain medication and talked about my concerns. They told me it was a necessary evil in this case so that I could sleep. The morning of surgery, after long discussion with the anesthesiologist, He asked if I had testing done to look at my response to different drugs. At that time, I didnt even know that was a thing that could be done.

The news media and medical media lately has talked a lot about epigenetics and epigenomics and we are starting to hear about pharmacogenetics. Pharmacogenetics can be done through DNA testing to specifically look at your genetics and how they might react to specific types of drugs. They can allow for better dosing, better drug choice so there is less guess work, and overall better outcomes. Pharmacogenetics can also help in looking at how some people may become addicted and others not to things like marijuana, which the Prop 64 group in Colorado would have us believe is not possible.

Pharmacogenetics can also let us know when it might be time to change a drug, because the epigenetics/epigenomics, or the environmental factors that cause the genes to change may have been affected over long-term use of specific drugs. These drugs can be related to addiction treatment, pain management, mental health disorders (bipolar, schizophrenia, depression), autoimmune logical drugs including chemotherapy.

Along the line of epigenetics/epigenomics, there is a specific testing that can be done that supports your DNA sections. It looks at what will optimally support your health, and with that information we can create a supplement that is SPECIFIC to you. Repeating the test about 6 months after initial testing and consuming of those supplements is recommended due to the changes you could potentially make. Then every year.

Why would you need a DNA-specific supplement? Colorado has one of the highest levels of radiation exposure in the continental U.S. Specifically, we have a lot of naturally occurring uranium and radon. Both of those are known carcinogens. Also, think about how much and what type of sunscreen you apply every year in Colorado while enjoying the outdoor lifestyle you love. Chemical barriers are more likely to interact with the radiation from the sun to create mutation of cells. It starts at the skin level, but quickly spreads to the body as the skin is an organ that ABSORBS things you put on it.

If you have questions about how DNA testing can improve your health, life and longevity, dont hesitate to reach out!

References:

*https://dnalife.academy/dna-health/

*Recent developments in genetic/genomic medicine, Rachel H. Horton and Anneke M. Lucassen, Clin Sci (Lond). 2019 Mar 15; 133(5): 697708.Published online 2019 Mar 5. Prepublished online 2019 Feb 27. doi: 10.1042/CS20180436

*Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry; Azmeraw T. Amare,1 Klaus Oliver Schubert,1,2 and Bernhard T. Baune1; EPMA J. 2017 Sep; 8(3): 211227.Published online 2017 Sep 5. doi: 10.1007/s13167-017-0112-8*Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants; Ramn Cacabelos,1,2,* Luca Fernndez-Novoa,1,2 Roco Martnez-Bouza,1,2 Adam McKay,1,2 Juan C. Carril,1,2 Valter Lombardi,1,2 Lola Corzo,1,2 Ivn Carrera,1,2 Ivn Tellado,1,2 Laura Nebril,1,2 Margarita Alcaraz,1,2 Susana Rodrguez,1,2 ngela Casas,1,2 Vernica Couceiro,1,2 and Antn lvarez1,2Pharmaceuticals (Basel). 2010 Oct; 3(10): 30403100.Published online 2010 Sep 29. doi: 10.3390/ph3103040*Some observations on the role of environment and genetics in behaviour of wild and domestic forms of Sus scrofa (European wild boars and domestic pigs)S Robert, J Dancosse, A Dallaire Applied Animal Behaviour Science, 1987 Elsevier

Read this article:
Genetics and Pharmacology | YourHub - The Know

VIENNA and SAN DIEGO, June 17, 2020 /PRNewswire/ -- Lexogen, a transcriptomics and Next Generation Sequencing company, and OnRamp Bioinformatics, a provider of cloud-based genomic analysis and collaboration tools, announced availability for the QuantSeq 3' mRNA-Seq data analysis pipeline on ROSALIND, the globally recognized discovery platform for scientists and researchers. The partnership enhances QuantSeq 3' mRNA-Seq data analysis with ROSALIND's visual data exploration and deep pathway interpretation with more than 50 knowledge bases.

Lexogen's QuantSeq 3' mRNA-Seq is a straightforward, fast, and cost-efficient method for library preparation. It has been widely used for expression profiling analysis and is currently featured in more than 470 publications. "QuantSeq is a well-established library preparation kit, validated by researchers who have used it for a broad range of applications. We are continuously enhancing the workflow based on the user feedback, and offering a complete solution including data analysis has always been top priority", said Dalia Daujotyte, Chief Commercial Officer at Lexogen.

As a platform for scientists, ROSALIND empowers QuantSeq 3' customers to analyze, interpret and collaborate globally on differential gene expression analysis without the need for specialized bioinformatics or programming skills. "Through our collaborations, it is our goal to provide full transcriptome analysis solutions vetted by experts in their fields. Access to QuantSeq data processing on ROSALIND not only gives an opportunity to an in-depth gene expression analysis, but also enables collaboration and multi-omics work without leaving the environment", added Daujotyte.

"QuantSeq 3' has been a game-changer for our biotech and pharma clients adopting RNA-seq, with the compelling economics to support high volume and the ability to assess the whole transcriptome," said Tim Wesselman, CEO of OnRamp Bio. "With ROSALIND, QuantSeq users of every skill level are empowered to visually explore same day results, save valuable time and restore the thrill of discovery," added Wesselman.

The usage of ROSALIND for QuantSeq data analysis and interpretation will be demonstrated in the GenomeWeb webinar "Integration of 3'mRNA-Seq and ChIP-Seq Datasets to Disentangle Redundant Epigenetic Regulatory Mechanisms", taking place on June 18, 2020. Register here: bit.ly/2AN9URF

About Lexogen

Established in 2007, Lexogen is a transcriptomics and Next-Generation Sequencing company, focusing on the development of innovative methods for RNA analysis. Its portfolio includes multiple innovative and well-established protocols for RNA sequencing sample preparation, external RNA spike-in controls, as well as bioinformatics tools and sequencing services. Lexogen is a privately held company, headquartered in Vienna, Austria with a subsidiary in New Hampshire, US.

To learn more, visit http://www.lexogen.com and follow @lexogen.

Contact person:Jekaterina AleksejevaSenior Marketing ManagerTel.: +43 699 1023 8946Email: jekaterina.aleksejeva@lexogen.com

About OnRamp Bioinformatics

OnRamp BioInformatics is the San Diego genomics software company that develops and maintains the ROSALIND discovery and collaboration platform designed for biologists and researchers. ROSALIND is globally deployed and trusted by top pharma, biotech and research institutions as the leading cloud platform for transcriptomics and epigenetics with comprehensive QC, deep pathway interpretation, advanced multi-omic meta-analyses and collaborative gene signatures.

To learn more, visit http://www.onramp.bio and follow us on Twitter or LinkedIn (@OnRampBio).

Contact person:Cassandra ElwellInvestor Relations & Communications OfficerTel.: +1 855 766 7267 ext. 708Email: cassandra@onramp.bio

Logo - https://mma.prnewswire.com/media/472869/Lexogen_logo_Logo.jpg Logo - https://mma.prnewswire.com/media/1192411/Lexogen_Logo.jpg

HOME

SOURCE Lexogen

The rest is here:
Lexogen and OnRamp Bioinformatics partner to provide differential gene expression data analysis and interpretation for QuantSeq 3' mRNA-Seq users - PR...

WUXI, CHINA / ACCESSWIRE / June 3, 2020 / Lisen Imprinting Diagnostics Inc. ("Lisen" or "the company"), a US company headquartered with main operations in Wuxi, China which specializes on tumor epigenetics research for advancing early-stage cancer detection, announces a new epigenetic-based cancer diagnostic method. The technology which innovatively applied visualized epigenetic imprinting biomarkers has been published in the open access journal Clinical Epigenetics on May 24.

Lisen developed and patented the QCIGISH (Quantitative Chromogenic Imprinted Gene In-Situ Hybridization) technology - a novel approach in identifying, visualizing, and quantifying the biallelic and multiallelic expressions of an imprinted gene panel associated with cancer status. In a 1013-case clinical study involving ten different cancer types including bladder, breast, colorectal, esophageal, gastric, lung, pancreatic, prostate, skin and thyroid cancers, QCIGISH achieved 94% overall sensitivity and 92% overall specificity.

Dr. Chunxue Bai, chief physician and professor of Zhongshan Hospital of Fudan University, one of the corresponding authors said, "Epigenetic alterations which occur prior to morphological changes are involved in most cancers, but its application in cancer diagnosis is still limited. More practical and intuitive methods to detect the aberrant expressions from clinical samples using highly sensitive biomarkers are needed."

Using the QCIGISH technology, Dr. Bai and a group of researchers from Ohio State University, Johns Hopkins University, University of Texas, Fudan University, Tongji University, Chinese Navy Medical University, Jiangsu Jiangyuan Hospital, Chinese Academy of Medical Science, evaluated the normal and aberrant expressions measured using the imprinted gene panel to formulate diagnostic models, which could accurately distinguish the imprinting differences of normal and benign cases from cancerous tissues. The new method proved effective for many different cancer types.

"We believe that QCIGISH will become a practically useful and powerful clinical tool by effectively supplementing standard cytologic and histopathologic diagnosis for early-stage cancer detection", the paper's primary author Dr. Rulong Shen, a pathologist of Ohio State University Wexner Medical Center remarked.

Dr. Ning Zhou, Lisen's CEO and co-founder, and the paper's other corresponding author added, "We have barely scratched the surface. Our current research conceptually opens a new diagnostic area in epigenetics-based cancer detection and demonstrates strong potential for high throughput clinical application. We expect that this technology may go beyond a diagnostic technique to also provide information on prognostic and predictive markers of treatment response. We are excited to discover more imprinted gene cancer biomarkers, proceed with an even larger prospective validation and extend the capabilities of our technology to foster hope to cancer patients around the world."

About Cancer Early Detection and Epigenetics

The incidence of cancer is 18.1 million and the mortality is 9.6 million every year (GLOBOCAN 2018). The survival rate of cancer patients decreases dramatically from early to advanced stages. Therefore, early cancer detection plays a vital role in improving patients' long-term survival. However, this remains a huge clinical challenge due to the absence of sufficient morphological evidences to enable a definitive diagnosis. Epigenetic changes such as DNA methylation, histone methylation and acetylation, and expression status of imprinting genes which all occur at precancerous stages and promote carcinogenesis, could serve as sensitive biomarkers for early cancer detection.

About Lisen Imprinting Diagnostics, Inc.

Lisen Imprinting Diagnostics, Inc. is a US company registered in Delaware dedicated to the accurate and early identification of cancers at their most curable stages. By developing advanced cancer detection technology, Lisen hopes to provide a personalized pathway for patients towards effective therapies while avoiding unnecessary, costly and potentially futile treatment. Collaborating with various medical centers from Shanghai, Nanjing, Dalian, Hangzhou, Zhengzhou and Wuxi, China, Lisen has studied 6500+ clinical cases involving 12 different cancer types. The company holds 20 Chinese and international intellectual properties on early cancer detection.

For further information, contact:

Ning Zhou | 001-8016990666| zhou.ning@lisenid.comLisen, CEOLisen Imprinting Diagnostics Inc.66 Jinghui East Boulevard #5601Wuxi, Jiangsu 214135China

SOURCE: Lisen Imprinting Diagnostics Inc.

View source version on accesswire.com: https://www.accesswire.com/592713/Lisen-Imprinting-Diagnostics-Inc-Announces-a-New-Innovative-and-Highly-Accurate-Epigenetic-Solution-for-Early-Cancer-Detection

Continued here:
Lisen Imprinting Diagnostics Inc. Announces a New Innovative and Highly Accurate Epigenetic Solution for Early Cancer Detection - Benzinga

OXFORD, England--(BUSINESS WIRE)--Epigenetics company Base Genomics has launched with a team of leading scientists and clinicians to set a new gold standard in DNA methylation detection. The company has closed an oversubscribed seed funding round of $11 million USD (9 million GBP) to progress development of its TAPS technology, initially focusing on developing a blood test for early-stage cancer and minimal residual disease. The funding round was led by Oxford Sciences Innovation and also included investors with industry expertise in genomics and oncology.

DNA methylation is an epigenetic mechanism involved in gene regulation and has been shown to be one of the most promising biomarkers for detecting cancer through liquid biopsy. The existing industry standard for mapping DNA methylation degrades DNA and reduces sequence complexity, however, limiting scientific discovery and clinical sensitivity. Base Genomics new technology, TAPS, overcomes these issues and generates significantly more information from a given sample, creating new opportunities in research and the clinic.

"In order to realize the potential of liquid biopsies for clinically meaningful diagnosis and monitoring, sensitive detection and precise quantification of circulating tumour DNA is paramount, said Base Genomics CMO Anna Schuh. Current approaches are not fit for purpose to achieve this, but Base Genomics has developed a game-changing technology which has the potential to make the sensitivity of liquid biopsies a problem of the past."

First developed at Ludwig Institute for Cancer Research Branch at the University of Oxford, TAPS is a novel chemical reaction that converts methylated cytosine to thymine under mild conditions. Unlike the industry standard technology, bisulfite sequencing, TAPS does not degrade DNA, meaning that significantly more DNA is available for sequencing. TAPS also better retains sequence complexity, cutting sequencing costs in half and enabling simultaneous epigenetic and genetic analysis.

Genomic technologies with the power, simplicity and broad applicability of TAPS come along very infrequently, said Base Genomics CTO Vincent Smith. It has the potential to have an impact on epigenetics similar to that which Illumina's SBS chemistry had on Next Generation Sequencing.

Base Genomics is led by a highly experienced team of scientists and clinicians, including Dr Vincent Smith, a world-leader in genomic product development and former Illumina VP; Dr Anna Schuh, Head of Molecular Diagnostics at the University of Oxford and Principal Investigator on over 30 clinical trials; Drs Chunxiao Song and Yibin Liu, co-inventors of TAPS at the Ludwig Institute for Cancer Research, Oxford; and Oliver Waterhouse, previously an Entrepreneur in Residence at Oxford Sciences Innovation and founding team member at Zinc VC.

The ability to sequence a large amount of high-quality epigenetic information from a simple blood test could unlock a new era of preventative medicine, said Base Genomics founder and CEO Oliver Waterhouse. In the future, individuals will not just be sequenced once to determine their largely static genetic code, but will be sequenced repeatedly over time to track dynamic epigenetic changes caused by age, lifestyle, and disease.

Visit link:
Base Genomics Announces Company Launch and Raises $11 Million USD to Commercialize Epigenetic Technology for Early and Sensitive Detection of Cancer...

Professor Reik is an internationally renowned expert in the field of epigenetics and has led the Institutes Epigenetics research programme since 2008. He has been the Institutes Associate Director since 2004.

Professor Peter Rigby, FRS, Chair of the Institutes Board of Trustees, said: I am delighted to announce that the Institute Board has appointed Professor Wolf Reik FRS as the Acting Director of the Babraham Institute. Professor Reik is a world-class scientist, internationally renowned for his work in epigenetics, who has been at the Institute for over 30 years. The BBSRC fully support the Board's appointment, which will ensure the Institute continues to be strongly led, building on the excellent work of Professor Michael Wakelam. I know that Wolf will provide much needed leadership and stability during the uncertain times that we all face.

Professor Reik commented: I am really honoured by this appointment; I look forward to working with everyone at the Institute, the Campus and with BBSRC. After Michaels sad death, my primary aim is to bring us back to our labs in a safe and considerate fashion, and to jointly tackle the opportunities and challenges for the science of the Institute going forward strongly into the future.

Professor Reiks research centres on understanding the role of epigenetics (non-sequence altering modifications to DNA or chromatin that regulate gene expression) in establishing cell fate and identity during mammalian development and also the process of epigenetic reprogramming. The research interests of his lab span understanding the epigenetic processes governing the earliest steps of development, how pluripotency is maintained in stem cells and conversely how cell identity is established during differentiation. More recently the lab is interested in how the epigenome degrades during ageing, and whether there are ways of reversing this decay. They have developed new technologies for single cell multi-omics sequencing which allows unprecedented insights into cell fate changes during development or ageing. Professor Reik enjoys collaborating with scientists in the Institute and outside, and leads a Wellcome-funded consortium that studies cell fate decisions during mouse gastrulation and organ development.

Professor Reik is honorary Professor of Epigenetics and Affiliate Faculty at the Stem Cell Institute at the University of Cambridge and Associate Faculty at the Wellcome Sanger Institute. He is a member of EMBO and the Academia Europaea (elected in 2003 and 2011, respectively), and a Fellow of the Academy of Medical Sciences (2003) and of the Royal Society (2010). Professor Reik has been a member of funding committees of several of the UKs key research funders such as UKRI-Medical Research Council, Cancer Research UK and Wellcome Trust.

Professor Reik obtained his MD from the University of Hamburg in 1985. He undertook his thesis work with Rudolf Jaenisch in Hamburg, followed by postdoctoral work with Azim Surani at the Institute of Animal Physiology, now the Babraham Institute. During this time, he became a Fellow of the Lister Institute of Preventive Medicine which provided funding to start his own independent research group (in 1987).

Image: Professor Wolf Reik. Courtesy of Keith Heppell and the Cambridge Independent.

Read the rest here:
Professor Wolf Reik FRS appointed Acting Director of the Babraham Institute - Cambridge Network

Memories, nature, and instincts are some of the few things that make us. Where do these come from? From us, parents, grandparents, and so on. In Assassins Creed games, you visit your ancestors memories with the help of a machine named Animus. With this fascinating concept in mind, it makes us wonder how close or far are we from this science-fiction.

Do we have ancestral memories? Do memories pass along? Is there technology to process these memories? Lets see.

As far asAssassins Creedgoes, memories of ancestors are passed down from their bloodline. So, Desmond (present-day hero) can relive Altairs (1000 AD Assassin) memories because of this. Similarly, you could relive memories of ancestors in your bloodline, for instance. Youd simply lay down on the Animus and let it play memories like a VR game.

In our world, memories are said to be stored in our brains exclusively. It is accurate but there is still more to it. You see, since time immemorial scientists have suggested that ancestors pass down traits, impulses, etc. as part of evolution. These traits stemming from certain memories. Also, this applies to animals as well. Darwin, for instance, had the theory of pangenesis. Basically, it entailed that a body emits tiny particles called gemmules which pass on to offsprings. This theory was similar to Lamarckism. Both theories were dismissed in those days.

However, more recent experiments led to a new field of study called epigenetics which makes the earlier theories credible. In simple terms, epigenetics means the working of DNA instead of DNA itself. Consider meta-data. If you have songs, thats DNA. Adding shuffle, repeats, skips, playlists, etc to it is epigenetics.

Carl Jung, a famous psychologist, invented a theory named collective unconscious. It suggests that certain aspects such as fears, instincts, memories, etc. encompass all of our species. Also, it says that we inherit certain traits in our genes. Freud believed this to be due to personal experiences. That said, Jungl believed humans could tap into this unconscious only when necessary. The word Animus, also means memory.

Here, epigenetics prove helpful. Research has found genetically mutated roundworms to live 30% more than expected. Furthermore, the offsprings of those worms had a greater life-span as well. We already know our DNA indicates life-span. Epigenetics goes ahead and makes the changes by on and off switches in our genes. Genes are nothing but instructions in DNA. Through epigenetic methods, research shows potential ways of determining if a young bee (or larva) will become a queen bee. Roundworms and bees are more direct examples of epigenetics. The Aplysia experiment too.

Environmental and external factors also take part in epigenetics. Descendants of slaves, refugees, war prisoners, calamity survivors, etc. are a few types of people said to have altered genes. The Dutch Famine is an example. The people who went through the famine had smaller than average children. Also, they had a higher risk of diabetes and other health issues. The same was seen for later generations.

Desmond, inAssassins Creed,learns his ancestors traits and abilities. Considering the above two paragraphs, maybe thats how Ubisoft got the idea. InAssassins Creed, it is called bleeding effect.

Epigenetics might show us that memories, traits, and such do reside in our genes or DNA. However, it wouldnt mean much if there was no technology to bring those memories in front of us.

Various scientific bodies, including Microsoft, have looked into the idea of DNA-based storage devices. In recent years, teams have automated the read-and-write process of data onto DNA. How does it work? In simple terms, genetic bases are represented by chemical letters A, C, G, and T. Now, these letters can be converted to binary, 1s and 0s. Computers deal with binaries and not the letters.

DNA-based data storage has a better density (grams of DNA capable of holding thousands of GB), can last millennia, and can be replicated easily. Although, this is expensive and slow. So, right now companies are making efforts to speed up this process and make it accessible to many people. For instance, Microsofts Purple Drop project.

Intel, Catalog, etc are also finding ways of making DNA-based storage the mainstream storage of tomorrow. In other words, you might one day store your life memories into a pen-drive for your children to see. An advanced version of a photo album, you could say.

Till then, well just wait forAssassins Creed: Valhalla!

Here at FictionTalk, we look into the science that goes behind interesting stories all around us! If you want more, visit our take on Science Behind Time Perception Drugs and Science Behind Frankenstein.

Go here to see the original:
The Science Behind Reliving Memories: Animus from Assassins Creed - Fiction Talk

An utter way to forecast what future holds is to comprehend the trend today which has been followed while preparing this Epigenetics-Based Instruments market report and chewing over several fragments of the present and upcoming market scenario. The Epigenetics-Based Instruments market report encompasses company profiling of key players in the market, carefully analyzing their core competencies, and drawing a competitive landscape for the market. It is always important to have valuable and actionable market insights for creating sustainable and profitable business strategies. This Epigenetics-Based Instruments market report endows with the plentiful insights and business solutions that will help to stay ahead of the competition.

Get Sample Copy Of This Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-epigenetics-based-instruments-market

Few of the major competitors currently working in the global epigenetics-based instruments market arePacific Biosciences of California, Inc.; 10x Genomics; Illumina, Inc.; Merck KGaA; QIAGEN; Eisai Co., Ltd.; Novartis AG; Diagenode s.a.; Zymo Research; Active Motif, Inc.; Thermo Fisher Scientific Inc.; Agilent Technologies, Inc.; Bio-Rad Laboratories, Inc.; Bio-Techne among others.

Key Developments in the Market:

Market Drivers

Market Restraints

Inquiry For Customize Report With Discount at :https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-epigenetics-based-instruments-market

Segmentation: Global Epigenetics-Based Instruments Market

By Product

By Technology

By Application

By End-Users

ByGeography

Get Full Table Of content @https://www.databridgemarketresearch.com/toc/?dbmr=global-epigenetics-based-instruments-market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. GetCustomizationandDiscounton Report by emailing[emailprotected]. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email: [emailprotected]

Read more:
Global Epigenetics-Based Instruments Market To Witness Robust Expansion Throughout the Forecast Period 2019-2026|Pacific Biosciences of California,...

Diagenode

Global Epigenetics Market Segmentation

This market was divided into types, applications and regions. The growth of each segment provides an accurate calculation and forecast of sales by type and application in terms of volume and value for the period between 2020 and 2026. This analysis can help you develop your business by targeting niche markets. Market share data are available at global and regional levels. The regions covered by the report are North America, Europe, the Asia-Pacific region, the Middle East, and Africa and Latin America. Research analysts understand the competitive forces and provide competitive analysis for each competitor separately.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=212734&utm_source=LHN&utm_medium=888

Epigenetics Market Region Coverage (Regional Production, Demand & Forecast by Countries etc.):

North America (U.S., Canada, Mexico)

Europe (Germany, U.K., France, Italy, Russia, Spain etc.)

Asia-Pacific (China, India, Japan, Southeast Asia etc.)

South America (Brazil, Argentina etc.)

Middle East & Africa (Saudi Arabia, South Africa etc.)

Some Notable Report Offerings:

-> We will give you an assessment of the extent to which the market acquire commercial characteristics along with examples or instances of information that helps your assessment.

-> We will also support to identify standard/customary terms and conditions such as discounts, warranties, inspection, buyer financing, and acceptance for the Epigenetics industry.

-> We will further help you in finding any price ranges, pricing issues, and determination of price fluctuation of products in Epigenetics industry.

-> Furthermore, we will help you to identify any crucial trends to predict Epigenetics market growth rate up to 2026.

-> Lastly, the analyzed report will predict the general tendency for supply and demand in the Epigenetics market.

Have Any Query? Ask Our Expert@ https://www.marketresearchintellect.com/need-customization/?rid=212734&utm_source=LHN&utm_medium=888

Table of Contents:

Study Coverage: It includes study objectives, years considered for the research study, growth rate and Epigenetics market size of type and application segments, key manufacturers covered, product scope, and highlights of segmental analysis.

Executive Summary: In this section, the report focuses on analysis of macroscopic indicators, market issues, drivers, and trends, competitive landscape, CAGR of the global Epigenetics market, and global production. Under the global production chapter, the authors of the report have included market pricing and trends, global capacity, global production, and global revenue forecasts.

Epigenetics Market Size by Manufacturer: Here, the report concentrates on revenue and production shares of manufacturers for all the years of the forecast period. It also focuses on price by manufacturer and expansion plans and mergers and acquisitions of companies.

Production by Region: It shows how the revenue and production in the global market are distributed among different regions. Each regional market is extensively studied here on the basis of import and export, key players, revenue, and production.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Epigenetics Market Size, Epigenetics Market Growth, Epigenetics Market Forecast, Epigenetics Market Analysis

Our Trending Reports

Wireless Gamepad Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Wireless Local Area Network (WLAN) Devices Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read the original post:
Epigenetics Market Overview, Top Companies, Region, Application and Global Forecast by 2026 - Latest Herald

IPSWICH, Mass., April 27, 2020 /PRNewswire/ -- New England Biolabs (NEB)today announced a transition to a 100% recyclable alternative to expanded polystyrene (EPS) for shipment of most of its products. The new packaging was developed by TemperPack, a U.S. company that focuses on providing sustainable solutions for cold chain shipping. While fully recyclable, this new packaging maintains the proper shipping temperature conditions for its products.

Cold chain shipping has always been a challenge from an environmental standpoint. Enzymes and reagents often require shipment on ice or dry ice, and maintaining shipping temperature is critical, particularly when shipping long distances or to warmer climates. EPS has historically been the "gold standard" for cold shipping, as it is light, durable, and well-known for its insulative properties. Unfortunately, EPS is difficult to recycle, and often makes its way to landfills.

To address this, NEB's new shipping box will use the ClimaCell insert, which is paper-based and can maintain the required temperature conditions for the duration of a product's delivery time. The entire box is recyclable, with other corrugated cardboard, after unpacking.

"NEB has always placed environmental stewardship as one of our highest priorities," said Jim Ellard, CEO of NEB. "We are continuously working to promote ecologically sound practices and environmental sustainability, to protect our natural resources both locally and globally. It is our goal to continuously improve our business processes to minimize our impact on the environment. Transitioning to a 100% recyclable solution for shipping our products represents an important step in achieving this goal."

"We are excited to partner with NEB in its efforts to implement a more sustainable solution for its shipping process," said James McGoff, founder of TemperPack. "Not only are they helping to eliminate EPS from landfills, but the transition to the ClimaCell shipper represents a 25% reduction in carbon emissions."

NEB's ClimaCell cooler will begin to replace EPS shipments in the U.S. in late April / early May 2020. For a minority of NEB products that still rely on EPS, specifically those that require shipment on dry ice, NEB will maintain its shipping box recycling program, which allows customers to use a free return label to send their EPS shipping box back to NEB for re-use.

To learn more about NEB's ClimaCell cooler, visit http://www.neb.com/ShippingBox

About New England BiolabsNew England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, library preparation for next generation sequencing, cellular analysis, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company, headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and eight subsidiaries located in Australia, Canada, China, France, Germany, Japan, Singapore and the UK. For more information about New England Biolabs visit http://www.neb.com.

About TemperPackTemperPack makes packaging that works for businesses, people, and the planet. The company was borne out of a desire to reduce the amount of unsustainable packaging caused by the rise of e-commerce and perishable delivery. Incorporating environmental responsibility into product design, the company specializes in bringing the highest quality packaging solutions to scale. Operating an ISTA certified ThermalTransport Lab and state-of-the-art production facilities in Richmond, VA and Las Vegas, NV, the company is rapidly expanding its reach in the perishable food and life sciences industries. Our mission is simple: protect products with packaging that protects the planet. To learn more, visit http://www.temperpack.com.

NEW ENGLAND BIOLABS and NEB are registered trademarks of New England Biolabs, Inc.CLIMACELL and TEMPERPACK are registered trademarks of TemperPack Technologies, Inc.

See original here:
New England Biolabs Introduces 100% Recyclable Packaging for Cold Chain Shipping in Partnership with TemperPack - Tewksbury town crier